Micromedic develops biomarkers for specific diseases.
Biomarker developer Micromedic Technologies Ltd. (TASE:MCTC) has named Dun & Bradstreet Israel general manager Reuven Kuvent as chairman, replacing chairman David Solomon who will become CEO of the company.
Micromedic collaborates with several top research institutes, including the Technion Israel Institute of Technology, Hadassah Medical Organization, and the University of Florida. The company buys the rights to develop biomarkers, which indicate certain diseases, from the research institutes in exchange for royalties from any future sales. The company carries out clinical trials to test a biomarker's ability to diagnose an illness, and, if successful, commercializes the product.
Solomon said, "I welcome Kuvent to the company as chairman."
Published by Globes [online], Israel business news - www.globes-online.com - on December 9, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007